Cellenkos to test CK0801 for bone marrow failure syndromes treatment
Category: #health  By Mateen Dalal  Date: 2019-06-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cellenkos to test CK0801 for bone marrow failure syndromes treatment

Cellenkos Inc., an early stage clinical biotechnology company recently announced initiation of Phase 1 clinical trial of CK0801 for treatment of bone marrow failure syndromes, including primary myelofibrosis, hypoplastic myelodysplasia & aplastic anemia, cites source.

For the record, bone marrow failure syndrome denotes a group of life-threatening diseases with malfunctioned production of white blood cells (that lead to severe infection), red blood cells (that leads to anemia) & platelets (that leads to bleeding). Uncontrolled inflammation, immune dysfunction & defective T-regulatory cells propagate bone marrow failure syndromes.

Bone marrow failure syndrome is indicated by disease-driving cytotoxic T-cells’ uncontrolled attacks leading to an inflammatory microenvironment & inhibited normal blood cell production in the bone marrow. CK0801 supplies healthy regulatory T-cells to suppress cytotoxic T-cells & bone marrow inflammation and aids normalization of blood cell production.

As per credible sources, CK0801 is developed from Cellenkos' patented manufacturing platform and is allogeneic, cord blood-derived T-regulatory cell product. It inhibits key drivers of inflammation to overcome immune dysfunction. It contains healthy regulatory T-cells that are derived from healthy donor’s cord blood units. CK0801 is manufactured at Cellenkos’ GMP manufacturing facility, Texas. In June 2018, first CK0801 was approved by USFDA.

Elizabeth J. Read, MD & Chief Technology Officer, Cellenkos was reportedly quoted saying that clinical trial of CK0801 for bone marrow failure syndromes is a significant event for Cellenkos. The company’s programs include advancement of cord blood-derived T-regulatory cells products which are used for treatment of hematologic diseases, neuro-inflammatory disorders, graft vs. host disease & autoimmune diseases. The company aims at validating the cellular product as safe & capable of providing clinical benefit to range of serious illnesses.

As per sources close to the matter, the clinical trial of CK0801 will be led by Tapan Kadi (MD, Assistant Professor of Leukemia at University of Texas MD Anderson Cancer Center, Texas).

Source credits: https://finance.yahoo.com/news/cellenkos-inc-initiates-phase-1-131700344.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...